Bicycle Therapeutics plc

Bicycle Therapeutics plc (BCYC) reported collaboration revenue of $72.6 million for FY 2025, a 106% YoY increase from $35.3 million in 2024, driven by accelerated recognition from Novartis and Bayer collaborations following termination notices. Despite revenue growth, the company posted a net loss of $219.0 million, widening 30% YoY from $169.0 million, due to surging R&D expenses at $240.3 million (up 39% YoY) from zelenectide pevedotin trials and discovery efforts. G&A rose 10% to $79.4 million. Loss from operations deepened to $247.1 million. Balance sheet strengthened with $628.1 million in cash equivalents, supporting operations into 2026 amid workforce reductions targeting 50% expense cuts. Operating cash burn hit $249.7 million, reflecting clinical investments. Strategic reprioritization focuses on nuzefatide pevedotin and BRC pipeline, deprioritizing zelenectide pevedotin. No product revenue yet; profitability hinges on clinical progress and partnerships. Cash position funds runway past 12 months, but ongoing losses signal need for funding.

Key Takeaways